Crinetics Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Crinetics Pharmaceuticals
CRNX Stock  USD 34.18  1.02  2.90%   
Crinetics Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Crinetics Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Crinetics Pharmaceuticals financial statements helps investors assess Crinetics Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Crinetics Pharmaceuticals' valuation are summarized below:
Gross Profit
-239.1 M
Market Capitalization
3.3 B
Enterprise Value Revenue
1.8 K
Revenue
1 M
Earnings Share
(3.69)
We have found one hundred twenty available fundamental signals for Crinetics Pharmaceuticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Crinetics Pharmaceuticals prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road.

Crinetics Pharmaceuticals Total Revenue

987,050

Check Crinetics Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crinetics Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 43.5 M, Interest Income of 43.5 M or Depreciation And Amortization of 760.2 K, as well as many indicators such as Price To Sales Ratio of 4.2 K, Dividend Yield of 0.0 or PTB Ratio of 3.27. Crinetics financial statements analysis is a perfect complement when working with Crinetics Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Crinetics Pharmaceuticals Correlation against competitors.
For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.

Crinetics Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.5 B1.4 B304.3 M
Slightly volatile
Short and Long Term Debt Total54.3 M51.7 M11.4 M
Slightly volatile
Other Current Liabilities46.7 M44.5 M10.8 M
Slightly volatile
Total Current Liabilities62.7 M59.7 M15.2 M
Slightly volatile
Other Liabilities7.4 M7 M1.9 M
Slightly volatile
Property Plant And Equipment Net58.4 M55.6 M12.4 M
Slightly volatile
Accounts Payable4.1 M5.9 M2.5 M
Slightly volatile
Cash277.8 M264.5 M69.3 M
Slightly volatile
Non Current Assets Total62.2 M59.2 M13.5 M
Slightly volatile
Non Currrent Assets Other3.8 M3.6 M673.1 K
Slightly volatile
Other Assets1.091.15408.2 K
Slightly volatile
Long Term Debt130.4 K146.7 K159.9 K
Slightly volatile
Cash And Short Term Investments1.4 B1.4 B284.7 M
Slightly volatile
Net Receivables11.3 M10.8 M2.6 M
Slightly volatile
Common Stock Total Equity406.3 M387 M146.9 M
Slightly volatile
Common Stock Shares Outstanding84.8 M80.8 M30.7 M
Slightly volatile
Long Term Debt Total130.4 K146.7 K159.9 K
Slightly volatile
Non Current Liabilities Total52.6 M50.1 M20.8 M
Slightly volatile
Capital Surpluse245.8 M234 M106.8 M
Slightly volatile
Other Current Assets22.4 M21.3 M5 M
Slightly volatile
Total Liabilities115.3 M109.8 M36.1 M
Slightly volatile
Property Plant And Equipment Gross66.5 M63.3 M14.1 M
Slightly volatile
Short and Long Term Debt39.2 K44.1 K48.1 K
Slightly volatile
Preferred Stock Total Equity26.1 M34.2 M24.5 M
Slightly volatile
Total Current Assets1.4 B1.4 B290.8 M
Slightly volatile
Non Current Liabilities Other1.6 M953.4 K829.5 K
Slightly volatile
Short Term Debt7.5 M7.2 M1.5 M
Slightly volatile
Common Stock2.4 B2.3 B485.7 M
Slightly volatile
Property Plant Equipment4.2 M5.7 M2.7 M
Slightly volatile
Net Working Capital1.4 B1.3 B276.8 M
Slightly volatile
Short Term Investments1.1 B1.1 B274.9 M
Slightly volatile
Deferred Long Term Liabilities19.7 K20.7 K1.8 M
Slightly volatile
Capital Stock2.4 B2.3 B485.8 M
Slightly volatile
Capital Lease Obligations54.3 M51.7 M13.5 M
Slightly volatile

Crinetics Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income43.5 M41.4 M6.8 M
Slightly volatile
Interest Income43.5 M41.4 M6.8 M
Slightly volatile
Depreciation And Amortization760.2 K1.3 M506.5 K
Slightly volatile
Selling General Administrative104.7 M99.7 M23.8 M
Slightly volatile
Total Revenue987 K1 M1.4 M
Slightly volatile
Other Operating Expenses356.9 M339.9 M88.4 M
Slightly volatile
Research Development252.2 M240.2 M65.2 M
Slightly volatile
Cost Of Revenue938.8 K988.2 K10.8 M
Very volatile
Total Operating Expenses356.9 M339.9 M88.4 M
Slightly volatile
Reconciled Depreciation2.9 M2.8 M752.6 K
Slightly volatile
Non Operating Income Net Other1.6 M1 M1.6 M
Pretty Stable

Crinetics Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation72.9 M69.4 M15.6 M
Slightly volatile
Begin Period Cash Flow63 M56.2 M42.9 M
Slightly volatile
Depreciation2.9 M2.8 M736.9 K
Slightly volatile
Capital Expenditures4 M3.8 M1.1 M
Slightly volatile
End Period Cash Flow279.1 M265.8 M69.7 M
Slightly volatile
Change To Netincome35.2 M33.5 M10.3 M
Slightly volatile
Change To Liabilities23.3 M22.2 M6.5 M
Slightly volatile
Issuance Of Capital Stock1 B970 M273.3 M
Slightly volatile
Change To Account Receivables11.5 M17.5 M5.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.2 K4 K1.3 K
Slightly volatile
Days Sales Outstanding7277652 K
Pretty Stable
Stock Based Compensation To Revenue70.1266.781520.3499
Slightly volatile
Capex To Depreciation1.351.38031.8118
Pretty Stable
EV To Sales4 K3.8 K1.2 K
Slightly volatile
Payables Turnover0.220.2313.6296
Slightly volatile
Sales General And Administrative To Revenue10195.993333.1305
Slightly volatile
Research And Ddevelopement To Revenue24323195.8922
Slightly volatile
Capex To Revenue3.883.69970.9611
Slightly volatile
Cash Per Share17.616.76185.6409
Slightly volatile
Days Payables Outstanding1.7 K1.6 K566
Slightly volatile
Income Quality0.910.75730.865
Slightly volatile
Net Debt To EBITDA1.20.62811.4397
Slightly volatile
Current Ratio13.6623.044515.6672
Slightly volatile
Receivables Turnover0.470.493.9072
Slightly volatile
Capex Per Share0.02850.04760.027
Slightly volatile
Revenue Per Share0.01220.01290.0568
Very volatile
Interest Debt Per Share0.670.64030.1906
Slightly volatile
Debt To Assets0.02380.03610.0254
Slightly volatile
Days Of Payables Outstanding1.7 K1.6 K566
Slightly volatile
Ebt Per Ebit1.070.88060.9831
Pretty Stable
Quick Ratio13.6223.044515.5965
Slightly volatile
Net Income Per E B T1.081.120.9971
Slightly volatile
Cash Ratio8.354.43249.9088
Slightly volatile
Days Of Sales Outstanding7277652 K
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.121.0171.033
Very volatile
Fixed Asset Turnover0.01780.01871.5985
Slightly volatile
Debt Ratio0.02380.03610.0254
Slightly volatile
Price Sales Ratio4.2 K4 K1.3 K
Slightly volatile
Asset Turnover7.0E-47.0E-40.0316
Slightly volatile

Crinetics Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap272.1 M306.1 M333.8 M
Slightly volatile
Enterprise Value359.8 M374.9 M332.1 M
Slightly volatile

Crinetics Fundamental Market Drivers

Cash And Short Term Investments1.4 B

Crinetics Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Crinetics Pharmaceuticals Financial Statements

Crinetics Pharmaceuticals investors use historical fundamental indicators, such as Crinetics Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Crinetics Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.2 M2.3 M
Total Revenue1 M987 K
Cost Of Revenue988.2 K938.8 K
Stock Based Compensation To Revenue 66.78  70.12 
Sales General And Administrative To Revenue 95.99  100.79 
Research And Ddevelopement To Revenue 231.14  242.70 
Capex To Revenue 3.70  3.88 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(326.13)(342.44)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY